Meloxicam/rizatriptan - Axsome Therapeutics

Drug Profile

Meloxicam/rizatriptan - Axsome Therapeutics

Alternative Names: AXS-07

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Axsome Therapeutics
  • Class Analgesics; Antimigraines; Antipyretics; Nonsteroidal anti-inflammatories; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Migraine

Most Recent Events

  • 28 Nov 2017 Axsome Therapeutics has patent protection for Meloxicam/rizatriptan (AXS-07) in USA
  • 28 Nov 2017 Investigation in Migraine in USA (PO)
  • 28 Nov 2017 Axsome Therapeutics plans a phase III trial for Migraine in USA, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top